Related Experiment Videos
Screening for treatable left ventricular abnormalities in diabetic patients
Adelle Dawson1, Allan D Struthers
1Department of Clinical Pharmacology & Therapeutics, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, Scotland, UK. a.z.dawson@dundee.ac.uk
Expert Opinion on Biological Therapy
|April 30, 2003
Summary
Diabetic patients often die from cardiovascular disease, not just coronary artery disease. Screening for left ventricular dysfunction and hypertrophy using B-type natriuretic peptide (BNP) can identify at-risk individuals for targeted therapy.
Area of Science:
- Cardiology
- Diabetology
- Biomarkers
Background:
- Cardiovascular disease is the primary cause of mortality in diabetic patients.
- Current prevention strategies predominantly focus on coronary artery disease.
- Left ventricular dysfunction (LVD) and left ventricular hypertrophy (LVH) are significant contributors to cardiac mortality in diabetes.
Purpose of the Study:
- To highlight LVD and LVH as critical, screenable cardiac complications in diabetes.
- To propose plasma B-type natriuretic peptide (BNP) as a prescreening tool for cardiac abnormalities.
- To emphasize the prognostic benefits of early detection and treatment of asymptomatic left ventricular abnormalities.
Main Methods:
- Review of existing literature on cardiovascular complications in diabetes.
- Discussion of the role of LVD and LVH in diabetic cardiac mortality.
- Proposal of plasma BNP as a biomarker for identifying patients requiring further cardiac evaluation.
Main Results:
- Coronary artery disease is not the only cause of cardiac death in diabetics.
- LVD and LVH are prevalent and treatable causes of cardiac mortality in this population.
- Plasma BNP levels can indicate the likelihood of underlying left ventricular abnormalities.
Conclusions:
- Screening for LVD and LVH in diabetic patients is crucial.
- Plasma BNP offers a potential method for prescreening to identify patients for echocardiography.
- Early identification and targeted therapy for left ventricular abnormalities improve outcomes in diabetic patients.